ArticleJournal of neuro-oncology2015
Current status of intratumoral therapy for glioblastoma.
Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Variability in the circulation of cerebrospinal fluid: causes and clinical implications for intraventricular drug delivery.Frontiers in drug delivery · 2026Review
- The glymphatic system in neurodegenerative diseases and brain tumors: mechanistic insights, biomarker advances, and therapeutic opportunities.Acta neuropathologica communications · 2025Review
- The glymphatic system in oncology: from the perspective of a radiation oncologist.Journal of radiation research · 2025Review
- Hyaluronic Acid Influences Amino Acid Metabolism via Differential L-Type Amino Acid Transporter 1 Expression in the U87-Malignant Glioma Cell Line.Advanced nanobiomed research · 2024Article
- Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme.ACS nano · 2023Article
- Human brain solute transport quantified by glymphatic MRI-informed biophysics during sleep and sleep deprivation.Fluids and barriers of the CNS · 2023Article
- Matrix Hyaluronic Acid and Hypoxia Influence a CD133Tissue engineering. Part A · 2022Article
- Integrating Diffusion Tensor Imaging and Neurite Orientation Dispersion and Density Imaging to Improve the Predictive Capabilities of CED Models.Annals of biomedical engineering · 2021Article
- Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma.Nanoscale · 2020Article
- Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model.Journal of neuroinflammation · 2020Article
- CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.Science advances · 2020Article
- Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Review
- A computational fluid dynamics approach to determine white matter permeability.Biomechanics and modeling in mechanobiology · 2019Article
- Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer.Pharmaceutics · 2019Review
- NDs@PDA@ICG Conjugates for Photothermal Therapy of Glioblastoma Multiforme.Biomimetics (Basel, Switzerland) · 2019Article
- Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior.Frontiers in materials · 2018Article
- Nanomaterials for convection-enhanced delivery of agents to treat brain tumors.Current opinion in biomedical engineering · 2017Article
- Advances in drug delivery to high grade gliomas.Brain pathology (Zurich, Switzerland) · 2016Review
- Photothermal therapy of glioblastoma multiforme using multiwalled carbon nanotubes optimized for diffusion in extracellular space.ACS biomaterials science & engineering · 2016Article
- Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.Patient preference and adherence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With emerging drug delivery technologies becoming accessible, more options are expected to become available to patients with glioblastoma (GBM) in the near future. It is important for clinicians to be familiar with the underlying mechanisms and limitations of intratumoral drug delivery, and direction of recent research efforts. Tumor-adjacent brain is an extremely complex living matrix that creates challenges with normal tissue intertwining with tumor cells. For convection-enhanced delivery (CED), the role of tissue anisotropy for better predicting the biodistribution of the infusate has recently been studied. Computational predictive methods are now available to better plan CED therapy. Catheter design and placement—in addition to the agent being used—are critical components of any protocol. This paper overviews intratumoral therapies for GBM, highlighting key anatomic and physiologic perspectives, selected agents (especially immunotoxins), and some new developments such as the description of the glymphatic system.
Indexed as
Identifiers
26233248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.